• Emily Payne, Kylee Harrington, Philomena Richard, Rebecca Brackin, Ravin Davis, Sarah Couture, Jacob Liff, Francesca Asmus, Elizabeth Mutina, Anyssa Fisher, Denise Giuvelis, Sebastien Sannajust, Bahman Rostama, Tamara King, Lisa M Mattei, Jung-Jin Lee, Elliot S Friedman, Kyle Bittinger, Meghan May, and Glenn W Stevenson.
• Department of Psychology, University of New England, Biddeford, ME, 04005.
• J Pain. 2021 Nov 1; 22 (11): 153015441530-1544.

AbstractThe present experiments determined the effects of the narrow-spectrum antibiotic vancomycin on inflammatory pain-stimulated and pain-depressed behaviors in rats. Persistent inflammatory pain was modeled using dilute formalin (0.5%). Two weeks of oral vancomycin administered in drinking water attenuated Phase II formalin pain-stimulated behavior, and prevented formalin pain-depressed wheel running. Fecal microbiota transplantation produced a non-significant trend toward reversal of the vancomycin effect on pain-stimulated behavior. Vancomycin depleted Firmicutes and Bacteroidetes populations in the gut while having a partial sparing effect on Lactobacillus species and Clostridiales. The vancomycin treatment effect was associated with an altered profile in amino acid concentrations in the gut with increases in arginine, glycine, alanine, proline, valine, leucine, and decreases in tyrosine and methionine. These results indicate that vancomycin may have therapeutic effects against persistent inflammatory pain conditions that are distal to the gut. PERSPECTIVE: The narrow-spectrum antibiotic vancomycin reduces pain-related behaviors in the formalin model of inflammatory pain. These data suggest that manipulation of the gut microbiome may be one method to attenuate inflammatory pain amplitude.Copyright © 2021 United States Association for the Study of Pain, Inc. Published by Elsevier Inc. All rights reserved.

30 keywords...

hide…